Beta: Sign in
Shares outstandingAs of 2026-08-11 · filed common shares: 9.45M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.43%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 1.77%
Short ratioDays to cover, as published by FINRA: 6.12
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 54.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 53.10%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Loading evidence for CLRB

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -124.17%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -88.70%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales: Sign in
Price / operating cash flow: Sign in
P/FCF: Sign in
EV / revenue: Sign in
EV / EBITDA: Sign in
EPSDiluted, TTM to Jun 26: -2.21
EPS (fwd): Sign in

Financial health

Cash & equivalentsas of Jun 26: $33.99M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $1.53M
Debt / equityas of Jun 26: 5.12%
Current ratioas of Jun 26: 6.66
Quick ratio: —
Operating cash flowTTM to Jun 26: -$19.47M
Free cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$10.85M
TTM revenue / diluted share: —

CLRB stock Statistics — Cellectar Biosciences, Inc. filings, insiders & smart money · Instaport